Biorestorative Therapies (NASDAQ:BRTX) and Evaxion A/S (NASDAQ:EVAX) Head-To-Head Comparison

Biorestorative Therapies (NASDAQ:BRTX – Get Free Report) and Evaxion A/S (NASDAQ:EVAX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Profitability

This table compares Biorestorative Therapies and Evaxion A/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biorestorative Therapies -3,088.27% -508.42% -230.94%
Evaxion A/S N/A -61.43% -34.23%

Earnings and Valuation

This table compares Biorestorative Therapies and Evaxion A/S”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biorestorative Therapies $357,870.00 5.25 -$14.24 million ($21.40) -0.06
Evaxion A/S $7.53 million 3.36 -$7.71 million ($1.21) -2.32

Evaxion A/S has higher revenue and earnings than Biorestorative Therapies. Evaxion A/S is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Biorestorative Therapies and Evaxion A/S, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biorestorative Therapies 1 1 0 0 1.50
Evaxion A/S 1 0 4 0 2.60

Evaxion A/S has a consensus price target of $11.25, indicating a potential upside of 300.64%. Given Evaxion A/S’s stronger consensus rating and higher probable upside, analysts plainly believe Evaxion A/S is more favorable than Biorestorative Therapies.

Insider & Institutional Ownership

69.4% of Biorestorative Therapies shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by company insiders. Comparatively, 41.6% of Evaxion A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility and Risk

Biorestorative Therapies has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.

Summary

Evaxion A/S beats Biorestorative Therapies on 10 of the 14 factors compared between the two stocks.

About Biorestorative Therapies

(Get Free Report)

BioRestorative Therapies, Inc. is a biotechnology company developing cell-based treatments for medical conditions with limited treatment options. Its work focuses primarily on regenerative medicine and uses adult stem cells in research and product development. The company’s lead program, BRTX-100, is an investigational treatment made from a patient’s own cultured bone marrow-derived mesenchymal stem cells. It is being developed for chronic lumbar disc disease. BioRestorative also researches its ThermoStem platform, which uses brown adipose-derived stem cells in programs aimed at metabolic and related disorders.

About Evaxion A/S

(Get Free Report)

Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to discover and develop immunotherapies and vaccines. Its research focuses on treatments for cancer and infectious diseases, with the goal of identifying targets that can prompt the immune system to recognize and attack disease. The company’s pipeline includes personalized cancer immunotherapy candidates, including EVX-01, as well as vaccine programs for cancer and infectious diseases. Evaxion uses proprietary AI platforms to analyze biological data and identify potential targets for these programs.

Receive News & Ratings for Biorestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biorestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.